Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Sees Significant Decrease in Short Interest

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) was the recipient of a significant decrease in short interest in the month of January. As of January 30th, there was short interest totaling 4,025,930 shares, a decrease of 16.7% from the January 15th total of 4,830,166 shares. Based on an average daily trading volume, of 751,145 shares, the days-to-cover ratio is presently 5.4 days. Currently, 5.7% of the company’s shares are short sold. Currently, 5.7% of the company’s shares are short sold. Based on an average daily trading volume, of 751,145 shares, the days-to-cover ratio is presently 5.4 days.

Insiders Place Their Bets

In related news, major shareholder Group Walters acquired 6,459,973 shares of the stock in a transaction dated Wednesday, December 31st. The stock was bought at an average cost of $1.20 per share, with a total value of $7,751,967.60. Following the purchase, the insider directly owned 13,509,973 shares of the company’s stock, valued at approximately $16,211,967.60. This represents a 91.63% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Matrix Capital Management Comp sold 7,500,000 shares of the company’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $1.33, for a total value of $9,975,000.00. Following the sale, the insider owned 6,459,973 shares of the company’s stock, valued at $8,591,764.09. This represents a 53.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 7,546,617 shares of company stock valued at $10,088,417. Insiders own 1.90% of the company’s stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Sivia Capital Partners LLC bought a new position in Zentalis Pharmaceuticals in the 4th quarter worth approximately $27,000. Catalyst Funds Management Pty Ltd bought a new position in shares of Zentalis Pharmaceuticals in the second quarter worth $31,000. Voleon Capital Management LP acquired a new position in shares of Zentalis Pharmaceuticals during the third quarter valued at $41,000. SG Americas Securities LLC raised its stake in shares of Zentalis Pharmaceuticals by 35.3% during the third quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock valued at $48,000 after purchasing an additional 8,236 shares in the last quarter. Finally, Qube Research & Technologies Ltd acquired a new stake in Zentalis Pharmaceuticals in the second quarter worth about $37,000.

Wall Street Analysts Forecast Growth

ZNTL has been the subject of several analyst reports. Wall Street Zen raised Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. Morgan Stanley reduced their target price on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 12th. Finally, Wedbush reaffirmed a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $5.00.

Zentalis Pharmaceuticals Trading Down 1.3%

NASDAQ ZNTL traded down $0.03 on Tuesday, hitting $2.36. 201,601 shares of the stock traded hands, compared to its average volume of 1,892,571. The stock has a 50-day moving average of $2.20 and a 200 day moving average of $1.76. Zentalis Pharmaceuticals has a twelve month low of $1.01 and a twelve month high of $3.95. The company has a market capitalization of $170.51 million, a P/E ratio of -1.14 and a beta of 1.72.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.